Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance
USP7 is a promising target for the development of cancer treatments because of its high expression and the critical functions of its substrates in carcinogenesis of several different carcinomas. Here, we demonstrated the effectiveness of targeting USP7 in advanced malignant cells showing high levels...
Main Authors: | Sol-Bi Shin, Chang-Hyeon Kim, Hay-Ran Jang, Hyungshin Yim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/22/8629 |
Similar Items
-
Dual Targeting of EGFR with PLK1 Exerts Therapeutic Synergism in Taxane-Resistant Lung Adenocarcinoma by Suppressing ABC Transporters
by: Sol-Bi Shin, et al.
Published: (2021-09-01) -
USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer
by: Ying Fu, et al.
Published: (2018-11-01) -
The expression and clinical significance of PLK1/p-PLK1 protein in NK/T cell Lymphoma
by: Zhiqi Zhang, et al.
Published: (2023-11-01) -
USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2
by: Jing Cui, et al.
Published: (2023-10-01) -
Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
by: Sol-Bi Shin, et al.
Published: (2019-05-01)